Overview:

Novel coronavirus SARS-CoV-2 has caused the pandemic of the respiratory diseases (COVID-19) around the world since 2020 (1). The spike glycoprotein (S) of coronavirus, a type I transmembrane protein containing two subunits, S1 and S2 is known to bind with host cells through the interaction with angiotensin-converting enzyme 2 (ACE2) and facilitate viral entry into the host cell (2). SARS-CoV-2 variant carrying Δ69-70 has been detected in human cases in Denmark and UK. Mutation Δ69-70 has been associated with increased viral infectivity. As new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (2, 3).

Gene Aliases:

2019-nCoV s1, SARS-CoV-2 spike S1, SARS-CoV-2 S1, novel coronavirus spike s1, nCov spike s1, coronavirus spike S1.

Genebank Number:

MN908947

Formulation:

Recombinant protein stored in 50mM sodium phosphate, pH 7.5, 300mM NaCl, 150mM imidazole.

References:

1. Zhou P, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579:270-89. 2. Tada T, et al: Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1. 3. Kemp SA, et al: Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion H69/V70. bioRxiv 2020.12.14.422555; doi: https://doi.org/10.1101/2020.12.14.422555